A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
SillaJen, Inc.
Pfizer
Amgen
Generic Devices Consulting, Inc.
Leaf Vertical Inc.
Genentech, Inc.
Hoffmann-La Roche
Amgen
Taiho Pharmaceutical Co., Ltd.
Pfizer
Novartis